Nafamostat and sepimostat identified as novel neuroprotective agents via NR2B N-methyl-D-aspartate receptor antagonism using a rat retinal excitotoxicity model

Fuwa M., Kageyama M., Ohashi K., Sasaoka M., Sato R., Tanaka M., Tashiro K.

2019
Scientific Reports

View publication

Therapeutic Area

Back of the eye (BOTE)
Categories

Preclinical development

Affiliations

Research and Development, Santen Pharmaceutical Co., Ltd, Nara, Japan; Global Alliances and External Research, Santen Pharmaceutical Co., Ltd, Nara, Japan; Department of Genomic Medical Sciences, Kyoto Prefectural University of Medicine, Kyoto, Japan

Related Publications

Atropine Ophthalmic Solution to Reduce Myopia Progression in Pediatric Subjects: The Randomized, Double-Blind Multicenter Phase II APPLE Study

Chia A, Ngo C, Choudry N, Yamakawa Y, Tan D

Efficacy of lutein supplements on macular pigment optical density in highly myopic individuals: A randomized controlled trial

Yoshida T.; Takagi Y.; Igarashi-Yokoi T.; Ohno-Matsui K.

Electrical, Electromagnetic, Ultrasound Wave Therapies, and Electronic Implants for Neuronal Rejuvenation, Neuroprotection, Axonal Regeneration, and IOP Reduction

Sharif, N.A.

View all Back of the eye (BOTE) publications

Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022